Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2019-12-13 Capital/Financing Update
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Karolinska Development publishes an update on the net profit effect of the portfolio company Aprea Therapeutics share price development and a prospectus supplement relating to the directed share issue
Capital/Financing Update Classification · 1% confidence The document is titled as an announcement: "Karolinska Development publishes an update on the net profit effect... and a prospectus supplement relating to the directed share issue...". It details specific corporate actions, including an update on an investment's share price effect and the publication of a prospectus supplement related to a directed share issue. This content strongly suggests an announcement related to financing activities, capital structure changes, or the publication of required offering documents. Since it explicitly mentions a 'prospectus supplement' and a 'directed share issue,' the most fitting category is Capital/Financing Update (CAP). It is not a full report (10-K, IR), an earnings release (ER), or just a notice of dividend (DIV). It is an announcement detailing financing/capital structure events.
2019-12-13 English
Karolinska Development offentliggör uppdatering av nettovinsteffekt av portföljbolaget Aprea Therapeutics aktiekursutveckling samt tilläggsprospekt avseende riktad nyemission till Bolagets konvertibel
Capital/Financing Update Classification · 1% confidence The document is a press release from Karolinska Development AB dated December 13, 2019. It announces two main items: an update on the net profit effect from an investment (Aprea Therapeutics stock performance) and the publication of a supplementary prospectus ('tilläggsprospekt') related to a directed new share issue ('riktad nyemission') to convertible bondholders. The text explicitly mentions that the supplementary prospectus has been prepared and is available on the company's website and DNB Markets' website. It also details investor rights regarding the prospectus. Since the document's primary function is to announce the availability and details of a formal document (the prospectus) related to a financing/capital event, and it is structured as a press release, it fits best under the category of announcing a corporate action or report. Given the content heavily revolves around the issuance of a prospectus related to a financing event (the directed new share issue), it strongly relates to capital activities. However, the document itself is an announcement *about* the prospectus being published, not the prospectus itself. The most fitting category for an announcement regarding the publication of a formal document, especially one related to financing/share issues, is often 'Report Publication Announcement' (RPA) if it's purely about the release, or 'Capital/Financing Update' (CAP) if the financing event is the core news. Since the core news is the publication of the prospectus for the directed new share issue, 'CAP' is highly relevant, but the structure is that of a publication announcement. Given the specific mention of the prospectus being available, 'RPA' (Report Publication Announcement) is a strong candidate, as it signals the release of a formal document. However, because the content is fundamentally about a 'riktad nyemission' (directed new share issue), 'CAP' (Capital/Financing Update) captures the substance better than just the announcement mechanism. Since the document is a press release announcing the completion/registration of a financing step and the availability of the required prospectus, 'CAP' is chosen as the primary classification for the underlying event being communicated, even though it's delivered via a publication announcement format. The document length (6699 chars) is substantial enough that it's not just a brief notice, but a detailed communication about the financing structure and the associated prospectus.
2019-12-13 Swedish
Acquirer of SEK 121 million of convertible loan in Karolinska Development commits to set-off and the subscription period in the directed share issue is extended
Capital/Financing Update Classification · 1% confidence The document is a press release dated December 12, 2019, announcing corporate actions related to financing: the extension of a subscription period for a directed share issue, a set-off commitment by an acquirer of convertible loans, and the company's ongoing liquidity needs. This content directly relates to fundraising, capital structure changes, and financing activities. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a formal regulatory filing like a DVA or DIRS. Since it is a specific announcement about financing, CAP is the most appropriate code.
2019-12-12 English
Förvärvare av 121 miljoner kronor konvertibellån i Karolinska Development ingår avtal om kvittning och teckningsperioden i den riktade nyemissionen förlängs
Capital/Financing Update Classification · 1% confidence The document is a press release dated December 12, 2019, detailing a transaction involving the acquisition and subsequent conversion/subscription of debt into shares via a directed new share issue ('Riktade nyemissionen'). Specifically, it announces the extension of the subscription period for this share issue to facilitate the conversion of outstanding convertible loans. This action directly relates to the company's capital structure and financing activities. The key elements are the settlement of debt through equity issuance and the extension of a financing period. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a formal dividend notice (DIV). Since it is an announcement detailing a specific financing event, CAP is the most appropriate classification.
2019-12-12 Swedish
Karolinska Developments portföljbolag Forendo Pharma ingår licens- och samarbetsavtal med globalt läkemedelsföretag
M&A Activity Classification · 1% confidence The document announces a significant business event: a portfolio company (Forendo Pharma) entering into a license and collaboration agreement with Novartis, including an equity investment. This type of announcement details corporate development, financing aspects (initial cash payment, milestones, royalties), and strategic partnerships. This fits best under 'Capital/Financing Update' (CAP) as it involves a major financing/investment component related to a portfolio company, or potentially 'Regulatory Filings' (RNS) as it is a mandatory disclosure under EU market abuse regulation (MAR). Given the specific nature of the announcement detailing financing terms and a major deal, 'CAP' is a strong candidate, but since it is a general press release announcing a material event that impacts the parent company's valuation and portfolio, and it doesn't fit perfectly into the other specific categories like ER, IR, or DIV, the most appropriate general category for material, non-financial-result announcements that aren't explicitly about M&A (TAR) or management changes (MANG) is often RNS, especially when it's a mandatory disclosure. However, the core of the news is a financing/collaboration deal. Reviewing the definitions, 'CAP' covers 'Updates on company fundraising, financing activities, or capital structure changes.' The Novartis investment component strongly supports CAP. Since this is a press release announcing a material event, and not a formal regulatory form like 10-K or a specific report, RNS is also plausible as a fallback. Given the explicit mention of Novartis making an 'aktieinvestering' (share investment) and the financial structure of the deal, CAP is the most specific fit among the options for this type of corporate development news.
2019-12-11 Swedish
Karolinska Development’s portfolio company Forendo Pharma enters license and collaboration agreement with leading pharma company
M&A Activity Classification · 1% confidence The document is a press release from Karolinska Development announcing a significant business event: a portfolio company (Forendo Pharma) entering a license and collaboration agreement with Novartis, including an equity investment. This type of announcement details corporate activity, strategic partnerships, and financing/investment aspects, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV). It is a material event disclosure. Since the definitions do not explicitly cover 'Material Event Press Release' or 'Strategic Partnership Announcement', I must select the closest fit. It involves financing/capital structure changes (equity investment) and major corporate transactions (licensing/collaboration). The 'Capital/Financing Update' (CAP) is the most appropriate category as it covers fundraising and financing activities, which this announcement heavily features through the Novartis equity investment and the structure of the deal funding future development. It is not a general regulatory filing (RNS) because it fits better under CAP.
2019-12-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.